在胰腺癌中通过SHP2/PI3K通路增强KRAS G12D抑制剂的敏感性
Man-Wei Hao1, Tian-Xing Zhang1, Dan Dong2
1School of Pharmaceutical Sciences, Jilin University, Changchun, 130021, China.
Medical oncology (Northwood, London, England)
|March 27, 2025
概括
有KRAS G12D突变的胰腺癌很难治疗. 将MRTX1133与SHP099或Buparlisib相结合,协同抑制了癌细胞生长并促进了细胞亡,提供了新的希望.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物开发 药物开发
背景情况:
- 胰腺癌经常含有KRAS G12D突变,这对治疗具有重大挑战.
- MRTX1133,一种针对KRAS G12D的新型非共价抑制剂,显示出潜力,但受阻力机制的限制.
研究的目的:
- 在KRAS G12D突变胰腺癌的临床前模型中,研究将MRTX1133与SHP099 (一种SHP2抑制剂) 或Buparlisib (一种PI3K抑制剂) 结合使用的疗效.
- 评估协同效应的潜力和克服对KRAS G12D抑制的抗性.
主要方法:
- 进行了细胞活力测试,以评估单剂和组合疗法对胰腺癌细胞系的影响.
- 亡试验被用来量化诱导受治疗反应的编程细胞死亡.
- 计算了组合指数,以确定协同作用,添加作用或对抗作用.
主要成果:
- 结合MRTX1133与SHP099或布帕利西布,证明了胰腺癌细胞增殖的协同抑制.
- 与单剂疗法相比,联合治疗显著增强了亡.
- 这些发现表明,双重抑制策略可以克服抵抗路径.
结论:
- 涉及MRTX1133与SHP099或Buparlisib的组合疗法在治疗KRAS G12D突变胰腺癌方面显著有前途.
- 这些新的组合可能为患有这种具有挑战性的疾病的患者提供了改善的临床结果.
更多相关视频
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
17.5K
06:57Utilizing High Resolution Ultrasound to Monitor Tumor Onset and Growth in Genetically Engineered Pancreatic Cancer Models
Published on: April 7, 2018
10.7K
相关概念视频
01:22PI3K/mTOR/AKT Signaling Pathway
3.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.3K
01:20The JAK-STAT Signaling Pathway
8.4K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.4K
03:03mTOR Signaling and Cancer Progression
3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.6K